Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
3B Blackbio Dx Ltd (3BBLACKBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532067 NSE: 3BBLACKBIO Medical Equipment/Supplies/Accessories | Small Cap | 3B Blackbio Dx Share Price
₹1,367 -40.65 (-2.89%)
As on 22-Sep'26 16:59
3B Blackbio Dx Ltd (3BBLACKBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532067 NSE: 3BBLACKBIO Medical Equipment/Supplies/Accessories | Small Cap | 3B Blackbio Dx Share Price
₹1,367 -40.65 (-2.89%)
As on 22-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹1,173 Cr.
Current Price
₹1,367
52-Week Low / High
₹1,084 / 1,750
TTM EPS
₹64.7
TTM Sales
₹153 Cr.
Book Value per Share
₹326.2
P/E Ratio
21.13
Lower than its 5-year historical median
Industry PE
129
Price to Book (P/B)
4.19
Lower than its 5-year historical median
Price to Sales (P/S)
7.66
Lower than its 5-year historical median
EV/EBITDA
13.31
Lower than its 5-year historical median
Dividend Yield
0.29%
Profitability Efficiency
Return on Equity (ROE)
19.41%
Outperforms industry median
Return on Capital Employed (ROCE)
26.03%
Outperforms industry median
Return on Assets (ROA)
17.54%
Operating Profit Margin
51.9%
Net Profit Margin
49.44%
Gross Profit Margin
67.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
28.01%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
51.94%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
48.57%
Asset Quality
Promoter Holding
40.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹271 Cr.
Equity
₹8.6 Cr.
Face Value
₹10
All Time Low / High
₹4.81 / 2350.00
Check Before You Invest
Quality
Very GoodValuation
FairCheck Valuation charts
Price Trend
Strong
Is 3B Blackbio Dx Ltd a good quality company?
3B Blackbio Dx Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does 3B Blackbio Dx Ltd performance compare with that of its Peers?
Revenue growth of 3B Blackbio Dx Ltd vs industry peers?
3B Blackbio Dx Ltd revenue CAGR is 27.29%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of 3B Blackbio Dx Ltd?
Promoters hold 40.95% of the 3B Blackbio Dx Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of 3B Blackbio Dx Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 58.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
3B Blackbio Dx Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.8% | 5.5% | 6.1% | 4.2% | 4.1% | 9.5% | 33.5% | 10.8% | 36.6% | 25.5% | - |
| Value Creation Index ⓘ | -0.7 | -0.6 | -0.6 | -0.7 | -0.7 | -0.3 | 1.4 | -0.2 | 1.6 | 0.8 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 15.7 | 13 | 15.6 | 12.1 | 13.5 | 14.4 | 15.5 | 12 | 70.7 | 90.5 | 100 |
| Sales YoY Gr. | - | -17.1% | 19.6% | -22.3% | 11.8% | 6.3% | 8.1% | -22.7% | 489.3% | 28% | - |
| Adj EPS ⓘ | 0.3 | 0.4 | 0.8 | 0.7 | 0.8 | 2.3 | 10.7 | 2.9 | 39.8 | 55.3 | 59.4 |
| YoY Gr. | - | 24.1% | 125% | -17.3% | 22.4% | 179.3% | 365.9% | -73% | 1283.3% | 38.7% | - |
| BVPS (₹) ⓘ | 17.3 | 17.3 | 17.6 | 24.6 | 27.7 | 30.2 | 31.9 | 32.3 | 265.8 | 318.4 | 334.3 |
| Adj Net Profit ⓘ | 0.2 | 0.2 | 0.5 | 0.4 | 0.6 | 1.7 | 8 | 2.2 | 34.2 | 47.4 | 51 |
| Cash Flow from Ops. ⓘ | 0.9 | 0.2 | -0.8 | 0.5 | 1.1 | 2.8 | 8 | 1.7 | 28.5 | 44.5 | - |
| Debt/CF from Ops. ⓘ | 8.5 | 33.4 | -7.6 | 13.7 | 3.2 | 0.7 | 0.3 | 1.2 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 21.5% | 46.3% | 80% | 28% | ||||
| Adj EPS ⓘ | 79.2% | 132.1% | 73% | 38.7% | ||||
| BVPSⓘ | 38.2% | 62.9% | 115.2% | 19.8% | ||||
| Share Price | 57.9% | 23.2% | 21.9% | -2.7% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.7 | 2.1 | 3.9 | 2.7 | 3.4 | 7.9 | 34.4 | 9 | 27.1 | 19 | 18.2 |
| Op. Profit Mgn % ⓘ | 6.6 | 8.2 | 7 | 3.6 | -1.8 | -8.4 | -7.9 | -7.8 | 49.6 | 55.1 | 54.9 |
| Net Profit Mgn % ⓘ | 1.2 | 1.8 | 3.3 | 3.6 | 4.5 | 12 | 51.6 | 18 | 48.4 | 52.4 | 51 |
| Debt to Equity ⓘ | 0.7 | 0.7 | 0.5 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 445 | 529 | 488 | 665 | 597 | 549 | 521 | 686 | 214 | 246 | 233 |
| Cash Conv. Cycle ⓘ | 203 | 273 | 288 | 425 | 389 | 357 | 318 | 427 | 121 | 149 | 202 |
Valuation of 3B Blackbio Dx - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 |
| Operating Expenses ⓘ + | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 |
| Operating Profit ⓘ | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 |
| Operating Profit Margin (%) | 8.7% | 15.9% | 23.4% | 31.0% | 32.3% | 66.1% | 46.0% | 47.1% | 44.5% | 51.9% |
| Other Income ⓘ + | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 |
| Interest ⓘ | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax ⓘ | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 |
| Tax ⓘ | 0 | 0 | 1 | 2 | 2 | 38 | 11 | 9 | 12 | 16 |
| Profit After Tax | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 |
| PAT Margin (%) | 1.9% | 7.0% | 14.8% | 22.5% | 26.6% | 50.2% | 39.9% | 41.9% | 43.3% | 49.4% |
| Adjusted EPS (₹) | 0.7 | 1.8 | 5.4 | 8.2 | 10.3 | 152.0 | 43.0 | 30.3 | 37.5 | 55.7 |
| Dividend Payout Ratio (%) | 0% | 16.90% | 9.30% | 6.10% | 6.80% | 0.70% | 24.40% | 8.30% | 8% | 7.20% |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 10 | 11 | 14 | 22 | 32 | 132 | 153 | 193 | 223 | 268 | |
| Debt + | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | |
| Minority Interest | -0 | 0 | 0 | 0 | 2 | 16 | 19 | 3 | 2 | 3 | |
| Trade Payables | 5 | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 4 | 2 | |
| Others Liabilities ⓘ | 1 | 1 | 7 | 3 | 4 | 40 | 14 | 13 | 18 | 22 | |
| Total Liabilities ⓘ | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | |
| Inventories | 3 | 4 | 4 | 5 | 4 | 5 | 7 | 8 | 8 | 9 | |
| Trade Receivables | 13 | 14 | 16 | 18 | 20 | 35 | 30 | 34 | 36 | 37 | |
| Cash Equivalents | 0 | 0 | 2 | 3 | 9 | 35 | 29 | 59 | 62 | 69 | |
| Others Assets ⓘ | 3 | 4 | 5 | 5 | 6 | 55 | 26 | 13 | 17 | 18 | |
| Total Assets ⓘ | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 |
| Cash Flow From Investing Activity ⓘ + | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -34 |
| Cash Flow From Financing Activity ⓘ + | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 |
| Net Cash Flow ⓘ | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 6 |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 3.26 | 10.47 | 27.55 | 28.99 | 28.15 | 138.73 | 22.59 | 14.98 | 15.42 | 19.41 |
| ROCE (%) | 6.8 | 12.52 | 23.8 | 28.04 | 32.29 | 179.46 | 29.92 | 20.24 | 21.21 | 26.03 |
| Asset Turnover Ratio | 0.77 | 0.7 | 0.84 | 0.7 | 0.71 | 1.9 | 0.42 | 0.3 | 0.32 | 0.35 |
| PAT to CFO Conversion(x) | N/A | 1 | 0.67 | 0.8 | 0.88 | 0.86 | 1.16 | 0.77 | 0.84 | 0.9 |
| Working Capital Days | ||||||||||
| Receivable Days | 261.70 | 290.60 | 239.30 | 274.10 | 242.80 | 44 | 146.60 | 188.70 | 172.80 | 137.70 |
| Inventory Days | 70 | 76.60 | 59.80 | 67.90 | 57.30 | 7.20 | 27.90 | 45.70 | 40.60 | 32.50 |
| Payable Days | 188.70 | 0 | 113.30 | 124.70 | 100.60 | 22.40 | 37.50 | 70.40 | 61.20 | 42.10 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
3B Blackbio Dx Ltd FAQs
The current trading price of 3B Blackbio Dx on 22-Sep-2026 16:59 is ₹1,367.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of 3B Blackbio Dx stood at ₹1,173.3 Cr
The latest P/E ratio of 3B Blackbio Dx as of 21-Sep-2026 is 23.02.
The latest P/B ratio of 3B Blackbio Dx as of 21-Sep-2026 is 4.09.
The 52-week high of 3B Blackbio Dx is ₹1,750 and the 52-week low is ₹1,083.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of 3B Blackbio Dx is ₹99.86 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that 3B Blackbio Dx Ltd is a good quality company.
The key valuation ratios of 3B Blackbio Dx Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of 3B Blackbio Dx Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About 3B Blackbio Dx Ltd
Kilpest India is one of India's leading agri-based companies. Kilpest is an ISO certified company and has representation in India in the field of agriculture business comprising crop protection products and public health products, bio products, micro-nutrients and mix fertilizers. The company has one of the most advance Research & Development facility at its Bhopal plant and also has Biological Research Centre. The products are manufactured to high international! BlS specifications with stringent quality control from raw material procurement to finished goods despatch.
The products are manufactured to high international / BIS specifications with stringent quality control from raw material procurement to finished goods despatch. The company's manufacturing process is complimented with the technical expertise and it has attained high standard suited to customer needs.
The company has a nationwide distribution network. Kilpest is also doing toll formulations for multinational industries. Products of Kilpest are exported to several countries. The company is listed on the Bombay Stock Exchange. It is also registered with D&B, D-V-N-S.
Products range of the company includes:
- Emulsifiable Concentrate
- Wettable Powder/Soluble Powders
- Garanules
- Dusting Powder
- Botanical Pesticides
- Spray Adjuvant Cone
- Flowering Stimulent / Yield Booster
- Insecticide For Public Health
- House Hold Insecticide
- Sampada (Micro-Nutrients) / Fytozyme (Plant Growth Stimulant)
Clientele:
- Directarate General of Supplies& Transport, New Delhi.
- Directarate Health Services Haryana, Chandigarh.
- Controller of Procurement, Material Organisation, Eastern Naval, Command, Visakhpatnam (NAVY).
- Western Railway, Mumbai.
- Central Railway, Mumbai.
- Directorate of Central Medical Stores Organisation, Gujarat, Gandhi Nagar.
- The Director General Medical Health and Family welfare, U. P. Lucknow.
- Central Warehousing Corporation, Delhi.
- Central Public Works Department, Kanpur & Bhopal.
- Food Corporation of India, Bhopal, Lucknow, Mumbai, Jaipur.
- Indian Farmers Fertilizer Co-operative Ltd. New Delhi.
- M. P. State Co-operative Marketing Federation Ltd. Jehangirabad, Bhopal
- Municipal Corporation, Bhopal/lndore, and many more
Achievements/ recognition:
An ISO certified company
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
